NCT02383238View on ClinicalTrials.gov

Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Dapagliflozin

10 mg, oral for 6 weeks

DRUG

Placebo

oral for 6 weeks

Trial Locations (1)

91054

University Erlangen-Nuernberg, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER

NCT02383238 - Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content | Biotech Hunter | Biotech Hunter